Epigallocatechin Gallate: meta-analysis of COVID-19 studies

All studies   Hospitalization   Serious outcomes   Cases   RCTs   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies 38% 2 1K Improvement, Studies, Patients Relative Risk Hospitalization 67% 1 1K Cases 1% 1 1K RCTs 38% 2 1K Prophylaxis 67% 1 1K Late 38% 1 114 Epigallocatechin Gallate for COVID-19 c19early.org June 2026 Favorsepigallocatechin gallate Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Zhu (RCT) 38% 0.62 [0.50-0.90] no improv. 30/76 23/38 aerosolized EGCG Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.015 Late treatment 38% 0.62 [0.50-0.90] 30/76 23/38 38% lower risk Kawai (RCT) 67% 0.33 [0.01-8.15] hosp. 0/503 1/500 green tea gargling Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Prophylaxis 67% 0.33 [0.01-8.15] 0/503 1/500 67% lower risk All studies 38% 0.62 [0.43-0.90] 30/579 24/538 38% lower risk 2 epigallocatechin gallate COVID-19 studies c19early.org June 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.013 Effect extraction pre-specified(most serious outcome) Favors EGCG Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kawai (RCT) 67% 0.33 [0.01-8.15] hosp. 0/503 1/500 green tea gargling Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Prophylaxis 67% 0.33 [0.01-8.15] 0/503 1/500 67% lower risk All studies 67% 0.33 [0.01-8.15] 0/503 1/500 67% lower risk 1 epigallocatechin gallate COVID-19 hospitalization result c19early.org June 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Favors EGCG Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kawai (RCT) 67% 0.33 [0.01-8.15] hosp. 0/503 1/500 green tea gargling Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Prophylaxis 67% 0.33 [0.01-8.15] 0/503 1/500 67% lower risk All studies 67% 0.33 [0.01-8.15] 0/503 1/500 67% lower risk 1 epigallocatechin gallate COVID-19 serious outcome c19early.org June 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Effect extraction pre-specified(most serious outcome) Favors EGCG Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kawai (RCT) 1% 0.99 [0.59-1.67] cases 27/503 27/500 green tea gargling Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.98 Prophylaxis 1% 0.99 [0.59-1.67] 27/503 27/500 1% lower risk All studies 1% 0.99 [0.59-1.67] 27/503 27/500 1% lower risk 1 epigallocatechin gallate COVID-19 case result c19early.org June 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.98 Favors EGCG Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Zhu (RCT) 38% 0.62 [0.50-0.90] no improv. 30/76 23/38 aerosolized EGCG Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.015 Late treatment 38% 0.62 [0.50-0.90] 30/76 23/38 38% lower risk Kawai (RCT) 67% 0.33 [0.01-8.15] hosp. 0/503 1/500 green tea gargling Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Prophylaxis 67% 0.33 [0.01-8.15] 0/503 1/500 67% lower risk All studies 38% 0.62 [0.43-0.90] 30/579 24/538 38% lower risk 2 epigallocatechin gallate COVID-19 Randomized Controlled Trials c19early.org June 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.013 Effect extraction pre-specified(most serious outcome) Favors EGCG Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Zhu (RCT) 38% 0.62 [0.50-0.90] no improv. 30/76 23/38 aerosolized EGCG Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.015 Late treatment 38% 0.62 [0.50-0.90] 30/76 23/38 38% lower risk Kawai (RCT) 67% 0.33 [0.01-8.15] hosp. 0/503 1/500 green tea gargling Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Prophylaxis 67% 0.33 [0.01-8.15] 0/503 1/500 67% lower risk All studies 38% 0.62 [0.43-0.90] 30/579 24/538 38% lower risk 2 epigallocatechin gallate COVID-19 peer reviewed studies c19early.org June 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.013 Effect extraction pre-specified(most serious outcome) Favors EGCG Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Zhu (RCT) 38% 0.62 [0.50-0.90] no improv. 30/76 23/38 aerosolized EGCG Improvement, RR [CI] Treatment Control Zhu (RCT) 57% 0.43 [0.26-0.70] no improv. 71 (n) 37 (n) aerosolized EGCG Zhu (RCT) 90% 0.10 [0.02-0.57] no improv. 71 (n) 37 (n) aerosolized EGCG Zhu (RCT) 74% 0.26 [0.10-0.72] no improv. 71 (n) 37 (n) aerosolized EGCG Zhu (RCT) 53% 0.47 [0.19-1.14] no improv. 71 (n) 37 (n) aerosolized EGCG Zhu (RCT) 38% 0.62 [0.23-1.72] no improv. 71 (n) 37 (n) aerosolized EGCG Zhu (RCT) 36% 0.64 [0.15-2.67] no improv. 71 (n) 37 (n) aerosolized EGCG Zhu (RCT) 9% 0.91 [0.18-4.50] no improv. 71 (n) 37 (n) aerosolized EGCG Kawai (RCT) 67% 0.33 [0.01-8.15] hosp. 0/503 1/500 green tea gargling Kawai (RCT) 67% 0.33 [0.01-8.15] progression 0/503 1/500 green tea gargling Kawai (RCT) 1% 0.99 [0.59-1.67] cases 27/503 27/500 green tea gargling Kawai (RCT) 18% 0.82 [0.44-1.55] cases 386 (n) 403 (n) green tea gargling Kawai (RCT) 18% 0.82 [0.42-1.56] cases 386 (n) 403 (n) green tea gargling Epigallocatechin gallate COVID-19 outcomes c19early.org June 2026 Favors EGCG Favors control